Kura Oncology, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2016; filed August 10, 2016. Kura is a clinical-stage biopharmaceutical company developing targeted oncology therapies. It had 21.4 million common shares outstanding as of August 4, 2016.
Business context and pipeline
- Lead candidate tipifarnib was being studied in Phase 2 trials for HRAS-mutated solid tumors, peripheral T-cell lymphoma, and lower-risk myelodysplastic syndromes. A Phase 2 CMML trial was planned for the second half of 2016.
- KO-947, an ERK inhibitor, was in IND-enabling development. Management expected to submit an IND in the second half of 2016 and begin a Phase 1 trial in the first half of 2017, subject to manufacturing and formulation progress.
- The menin-MLL program was in lead optimization, with development-candidate nomination targeted for the second half of 2016.
- The company had no approved products and no product sales revenue.
Financial position and results
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Research and development expense | $4.9 million in 2016; $4.4 million in 2015 | $9.6 million in 2016; $8.0 million in 2015 |
| General and administrative expense | $1.9 million in 2016; $1.5 million in 2015 | $4.2 million in 2016; $2.6 million in 2015 |
| Net loss | $6.7 million in 2016; $5.6 million in 2015 | $13.3 million in 2016; $10.1 million in 2015 |
| Net loss per share | $0.36 in 2016; $0.54 in 2015 | $0.72 in 2016; $1.47 in 2015 |
| Net cash used in operating activities | Not separately provided | $13.1 million in 2016; $7.9 million in 2015 |
- Net loss increased by $1.1 million for the quarter and $3.2 million for the six-month period, primarily reflecting higher operating expenses.
- Six-month R&D expense increased $1.6 million, driven mainly by higher outsourced clinical development, outsourced research, and personnel costs.
- Six-month G&A expense increased $1.7 million, primarily due to higher patent costs, personnel, professional and consulting fees, corporate expenses, and public-company costs.
- Other income was $0.5 million for the six months, including $0.5 million of related-party management fee income, $0.2 million of interest income, and $0.2 million of interest expense.
- Share-based compensation expense was $0.9 million for the first six months of 2016, compared with $1.1 million in the prior-year period.
Cash, liquidity, debt, and capital resources
- Cash and cash equivalents were $12.1 million and short-term investments were $68.0 million at June 30, 2016, for total cash, cash equivalents, and short-term investments of approximately $80.1 million.
- The company had an accumulated deficit of $39.6 million and total stockholders’ equity of $70.0 million at June 30, 2016.
- Cash declined by $3.3 million during the first six months of 2016. Operating cash use of $13.1 million was partly offset by $2.4 million of net investing cash inflows and $7.5 million of net debt proceeds.
- In April 2016, Kura borrowed $7.5 million under a term loan facility providing for up to $20.0 million. An additional $12.5 million was available between December 31, 2016 and May 1, 2017, subject to successful advancement of KO-947 into Phase 1 trials.
- The loan matures November 1, 2020, bears interest at the greater of 7.75% or prime plus 4.25%, and requires interest-only payments through May 1, 2018 followed by 30 monthly principal and interest payments.
- The debt is secured by substantially all current and future assets other than intellectual property, although proceeds from certain intellectual-property transactions are included as collateral. The company was in compliance with its material covenants at June 30, 2016.
- Management expected existing cash, investments, and available debt proceeds to fund current operations into 2018, but stated that substantial additional financing will be required.
Material changes, outlook, and risks
- Operating losses and cash use are expected to continue and likely increase as clinical development, regulatory preparation, public-company activities, and pipeline programs advance.
- The company expects to seek additional equity, debt, collaboration, partnership, or licensing financing. Additional capital may be unavailable or may dilute stockholders, impose restrictive covenants, or require relinquishing rights to product candidates.
- KO-947 manufacturing and formulation issues had delayed completion of clinical supplies and the IND submission; further delays could postpone or prevent the planned Phase 1 trial.
- Tipifarnib composition-of-matter patents were expected to expire in the second half of 2016 in the United States, Europe, and other jurisdictions, increasing generic competition and reliance on other patent and regulatory protections.
- Key risks include unsuccessful or delayed clinical trials, difficulty enrolling genetically defined patient populations, safety or efficacy failures, regulatory non-approval, companion-diagnostic development risk, reliance on contract research and manufacturing organizations, intellectual-property challenges, and loss of licensed rights.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective.
- Related-party arrangements remained material: research and development services from Wellspring were approximately $2.2 million for the first six months, while management fees and reimbursements from Araxes were approximately $0.5 million.
Investor verification checklist
- Verify the timing and enrollment status of tipifarnib trials, including the planned CMML study.
- Verify whether KO-947 manufacturing, formulation, IND submission, and Phase 1-start milestones were achieved.
- Assess cash burn against the stated funding runway and the conditions for accessing the additional $12.5 million of term-loan capacity.
- Review debt covenants, collateral provisions, interest obligations, final payment, unused commitment fee, and lender warrants.
- Evaluate the expiration and remaining scope of tipifarnib patents, regulatory exclusivity, and competing generic risks.
- Review related-party agreements, fees, accrued liabilities, and potential conflicts of interest.
- Confirm that future financing needs, clinical outcomes, manufacturing issues, and regulatory risks could materially affect valuation and continuity of operations.